NEW YORK, NY – PharmaGiant Corp. announced today a revolutionary new insight gleaned from extensive market research: patients, when given the choice, overwhelmingly prefer treatments that extend their lives rather than shorten them. The discovery, hailed as 'transformative' by company executives, is expected to reshape future drug development strategies.

“For years, we’ve operated under the assumption that patients were largely indifferent to their own mortality, or perhaps even secretly desired a swift, profitable exit,” stated Dr. Evelyn Thorne, Head of Existential Therapeutics at PharmaGiant. “But our latest data, derived from focus groups and advanced biometric feedback during clinical trials, indicates a strong, almost universal desire to simply… keep living. It’s truly humbling.”

Industry analysts are calling the finding a 'paradigm shift' that could lead to a new era of patient-centric drug design. PharmaGiant’s stock surged on the news, with investors anticipating a lucrative new market segment: 'The Not-Dying Demographic.' The company plans to leverage this insight by developing more medications that actively prevent death, rather than merely managing symptoms or providing 'comfort care' until the inevitable.

“We’re exploring innovative ways to package and brand this newfound desire for life,” added Thorne. “Think about it: who *wouldn’t* want to continue existing? The marketing potential is astronomical.” Early concepts include 'Life-Affirming Elixirs' and 'Mortality-Delaying Serums,' with a premium tier offering 'Eternal Wellness Solutions.'

Competitors are reportedly scrambling to replicate PharmaGiant’s research, with several major pharmaceutical firms launching their own 'Life Preference' divisions. One anonymous executive admitted, “Frankly, we just thought everyone was fine with the status quo. This changes everything.”

PharmaGiant is now considering a bold move to patent the concept of 'not dying' itself, ensuring future profitability.